OxSonics to present encouraging preclinical efficacy data from its collaboration with
ADC Therapeutics at the EORTC-NCI-AACR Symposium
SonoTran® provides increased efficacy of an antibody-drug conjugate (ADC) in a human renal cancer model
Oxford, UK – 12 October 2022 – OxSonics Therapeutics, a clinical-stage company focused on transforming cancer treatment through SonoTran®, its ultrasound-based drug delivery platform, announces that it will present a poster entitled ‘Ultrasound-induced cavitation enhances therapeutic efficacy of AXL-targeting ADC leading to improved survival in a human xenograft model of renal cancer’ on 28 October at the forthcoming EORTC-NCI-AACR Symposium in Barcelona, Spain from 26-28 October 2022.
SonoTran®, the Company’s proprietary technology platform, is being developed to enhance the delivery and improve the efficacy of oncology drugs. It is currently being evaluated in a phase I/IIa proof of concept clinical study in patients with metastatic colorectal cancer with liver metastases.
At EORTC-NCI-AACR, OxSonics will present preclinical data from its collaboration with ADC Therapeutics (NYSE: ADCT), investigating the combination of SonoTran® with ADC Therapeutics’ ADCT-601 candidate. The data, which utilised a human renal cancer model, demonstrates the potential of SonoTran® to enhance the efficacy of an antibody-drug conjugate.
|Title:||‘Ultrasound-induced cavitation enhances therapeutic efficacy of AXL-targeting ADC leading to improved survival in a human xenograft model of renal cancer’|
|Day/Date:||Friday 28 October|
|Session:||10:00-15:00 Drug delivery|
The full poster will be available from 28 October 2022, at https://oxsonics.com/scientific-publications/.
|Nicholas Adams, Chief Business Officer||+44 (0) 7712 448578|
|Walbrook PR (Media enquiries)|
|Stephanie Cuthbert / Phillip Marriage||+44 (0) 20 7933 8780 or firstname.lastname@example.org|
+44 (0)7796 794 663
About The EORTC-NCI-AACR Symposium
Hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR), the 2022 Symposium attracts academics, scientists and pharmaceutical industry representatives from across the globe to discuss the latest innovations in drug development, target selection and the impact of new discoveries in molecular biology. Further information on the conference can be found at: 34th EORTC-NCI-AACR Symposium – EORTC